2.32

0.85% -0.02

Lexicon Pharmaceuticals Inc (LXRX)

Overview News Price History Option Chain Financials Why LXRX Down? Discussions Forecast Stock Split

Lexicon Pharmaceuticals Inc stock is traded at $2.32, with a volume of 1.76M. It is down -0.85% in the last 24 hours and up +9.43% over the past month. Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Previous Close:

$2.34

Open:

$2.32

24h Volume:

1.76M

Relative Volume:

0.55

Market Cap:

$1.03B

Revenue:

$69.64M

Net Income/Loss:

$-26.09M

P/E Ratio:

-32.45

EPS:

-0.0715

Net Cash Flow:

$-38.80M

1W Performance:

-6.07%

1M Performance:

+9.43%

6M Performance:

+77.10%

1Y Performance:

+96.61%

1-Day Range:

$2.265

$2.335

1-Week Range:

$2.265

$2.49

52-Week Range:

$1.03

$2.68

Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile

Name

Lexicon Pharmaceuticals Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

(281) 863-3000

Address

2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS

Employee

Twitter

@LexPharma

Next Earnings Date

2026-08-05

Latest SEC Filings

LXRX's Discussions on Twitter

Compare LXRX vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LXRX Lexicon Pharmaceuticals Inc	2.32	1.05B	69.64M	-26.09M	-38.80M	-0.0715
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-05-25	Downgrade	Leerink Partners	Outperform → Market Perform
Jun-17-24	Initiated	H.C. Wainwright	Buy
Apr-30-24	Initiated	Leerink Partners	Outperform
Mar-07-23	Initiated	Jefferies	Hold
Aug-12-22	Initiated	Piper Sandler	Overweight
Jan-29-21	Upgrade	JP Morgan	Underweight → Neutral
Jan-29-21	Downgrade	Wedbush	Outperform → Neutral
Dec-08-20	Upgrade	Citigroup	Neutral → Buy
Nov-18-20	Upgrade	Gabelli & Co	Hold → Buy
Dec-11-19	Downgrade	Gabelli & Co	Buy → Hold
Nov-08-19	Downgrade	Citigroup	Buy → Neutral
Sep-11-19	Upgrade	Gabelli & Co	Hold → Buy
Jul-29-19	Downgrade	Stifel	Buy → Hold
Mar-25-19	Upgrade	Gabelli & Co	Sell → Hold
Jul-31-18	Reiterated	Stifel	Buy
Feb-23-18	Downgrade	Needham	Buy → Hold
Feb-14-18	Downgrade	JP Morgan	Neutral → Underweight
Mar-01-17	Reiterated	H.C. Wainwright	Buy
Mar-01-17	Reiterated	Wedbush	Outperform
Oct-07-16	Initiated	H.C. Wainwright	Buy
Aug-05-16	Reiterated	Wedbush	Outperform
Aug-02-16	Initiated	Citigroup	Buy
Mar-02-16	Reiterated	Wedbush	Outperform
Nov-09-15	Reiterated	Wedbush	Outperform
Sep-28-15	Upgrade	Gabelli & Co	Sell → Hold
Sep-18-15	Downgrade	Gabelli & Co	Hold → Sell
Aug-10-15	Downgrade	JP Morgan	Overweight → Neutral

View All

Lexicon Pharmaceuticals Inc Stock (LXRX) Latest News

Aug 12, 2026

Is Lexicon’s Earnings Slide And New Share Shelf Altering The Investment Case For Lexicon Pharmaceuticals (LXRX)? - simplywall.st

Aug 12, 2026

Aug 11, 2026

Lexicon Pharmaceuticals (STU:LX31) EV-to-OCF : -14.76 (As of Aug. 12, 2026) - GuruFocus

Aug 11, 2026

Analysts Have Made A Financial Statement On Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Second-Quarter Report - simplywall.st

Aug 11, 2026

Aug 10, 2026

Lexicon Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:LXRX) 2026-08-10 - Seeking Alpha

Aug 10, 2026

Renaissance Technologies LLC Increases Holdings in Lexicon Pharmaceuticals, Inc. $LXRX - MarketBeat

Aug 10, 2026